Glaxo Loses Court Effort to Block Generic Flonase
- Share via
From Bloomberg News
GlaxoSmithKline lost a bid to prevent sales of generic versions of its $900-million-a-year allergy drug Flonase.
Boehringer Ingelheim’s generic version could reach the market today after U.S. District Judge Andre Davis in Baltimore refused to block sales while Glaxo pursues a lawsuit against the Food and Drug Administration.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
